NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. This was originally TA963
The appraisal is expected to start during early-July 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-July 2024. The deadline for submissions is expected in approximately late-September 2024.